Characteristics and outcome of the 10 H pylori–negative patients treated with the Prevpac
. | . | ITP duration, y . | . | Treatment(s) at inclusion and daily dose(s) . | Plt count, × 109/L . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y (sex) . | . | Previous treatment(s) . | . | At inclusion . | After 3 mos . | After 6 mos . | Follow-up, mos . | Additional treatment for ITP (time after the PrevP ac) . | ||
| 1 | 15 (F) | 2 | pred, IVIg, anti-D, aza | pred 7.5 mg | 27 | 24 | 45 | 15 | IVIg (2 mos), ritux (3 mos) | ||
| 2 | 39 (F) | 15 | pred, spl, IVIg, anti-D | None | 23 | 12 | ND | 19 | IVIg (6 mos), ritux (7 mos) | ||
| 3 | 37 (F) | 1 | pred, IVIg | pred 5 mg, vit C 1 g | 43 | 38 | 246 | 16 | anti-D (2.5 mos); ritux (5 mos) (CR) | ||
| 4 | 16 (M) | 11 | IVIg, pred, aza | None | 9 | 7 | 391 | 20 | IVIg (1 d), spl (5 mos) (CR) | ||
| 5 | 28 (F) | 10 months | None | None | 60 | 98* | 156 | 15 | mmf (2 mos) (for an underlying SLE) | ||
| 6 | 55 (F) | 20 | pred, IVIg, spl, dan, aza, vcr, mmf, ritux, anti-CD40L | None | 8 | 10 | 6 | 19 | IVIg (1 d and then repeatedly), pred (1 mo) | ||
| 7 | 25 (F) | 11 | IVIg, pred, spl, dan, ritux | pred 5 mg, dan 400 mg | 14 | 7 | 25 | 20 | IVIg (1 d and then repeatedly) | ||
| 8 | 50 (F) | 6 | IVIg, pred, spl, anti-D, aza | None | 16 | 21 | 54 | 19 | IVIg (1 d and then repeatedly), ritux (3 mos) | ||
| 9 | 11 (F) | 8 | IVIg, spl | vit C 1 g | 16 | 29 | 20 | 19 | IVIg (3 d and then repeatedly) | ||
| 10 | 45 (F) | 3 | IVIg, anti-D | None | 40 | 62 | ND | 18 | None† | ||
. | . | ITP duration, y . | . | Treatment(s) at inclusion and daily dose(s) . | Plt count, × 109/L . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y (sex) . | . | Previous treatment(s) . | . | At inclusion . | After 3 mos . | After 6 mos . | Follow-up, mos . | Additional treatment for ITP (time after the PrevP ac) . | ||
| 1 | 15 (F) | 2 | pred, IVIg, anti-D, aza | pred 7.5 mg | 27 | 24 | 45 | 15 | IVIg (2 mos), ritux (3 mos) | ||
| 2 | 39 (F) | 15 | pred, spl, IVIg, anti-D | None | 23 | 12 | ND | 19 | IVIg (6 mos), ritux (7 mos) | ||
| 3 | 37 (F) | 1 | pred, IVIg | pred 5 mg, vit C 1 g | 43 | 38 | 246 | 16 | anti-D (2.5 mos); ritux (5 mos) (CR) | ||
| 4 | 16 (M) | 11 | IVIg, pred, aza | None | 9 | 7 | 391 | 20 | IVIg (1 d), spl (5 mos) (CR) | ||
| 5 | 28 (F) | 10 months | None | None | 60 | 98* | 156 | 15 | mmf (2 mos) (for an underlying SLE) | ||
| 6 | 55 (F) | 20 | pred, IVIg, spl, dan, aza, vcr, mmf, ritux, anti-CD40L | None | 8 | 10 | 6 | 19 | IVIg (1 d and then repeatedly), pred (1 mo) | ||
| 7 | 25 (F) | 11 | IVIg, pred, spl, dan, ritux | pred 5 mg, dan 400 mg | 14 | 7 | 25 | 20 | IVIg (1 d and then repeatedly) | ||
| 8 | 50 (F) | 6 | IVIg, pred, spl, anti-D, aza | None | 16 | 21 | 54 | 19 | IVIg (1 d and then repeatedly), ritux (3 mos) | ||
| 9 | 11 (F) | 8 | IVIg, spl | vit C 1 g | 16 | 29 | 20 | 19 | IVIg (3 d and then repeatedly) | ||
| 10 | 45 (F) | 3 | IVIg, anti-D | None | 40 | 62 | ND | 18 | None† | ||
Plt indicates platelet; mos, months; y, years; pred, prednisone; IVIg, intravenous immunoglobulin; anti-D, intravenous anti-D; aza, azathioprine; ritux, rituximab; spl, splenectomy; ND, not determined; vit C, vitamin C; d, day; mmf, mycophenolate mofetil; SLE, systemic lupus erythematosus; dan, danazol; vcr, vincristine; and anti-CD40L, anti-CD40 ligand monoclonal antibody.
The platelet increase was observed after 1 month of treatment with mmf.
Did not complete PrevPac.